Kiadis Pharma announces abstract accepted for presentation at the 2020 ISCT Annual Meeting
25 Maio 2020 - 3:35AM
Amsterdam, The Netherlands, May 25, 2020 –
Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext
Amsterdam and Brussels: KDS), a clinical stage
biopharmaceutical company, today announces an abstract highlighting
data related to the Company’s natural killer (NK) cell therapy
program has been accepted for presentation at the virtual edition
of the International Society of Cell & Gene Therapy (ISCT)
annual meeting taking place May 28 – 29, 2020.
The ISCT abstract is now available at http://www.isct2020.com/.
The details of the poster presentation are as follows:
·Poster #228: This poster presents data on a
method for high expansion of NK cells with “memory-like” phenotype.
This method combines pre-activation of NK cells with cytokines
(IL-12, IL-15, IL-18) and expansion with Kiadis’ PM21-particle
platform.
Abstract Details Title:
Cytokine pre-activation enhances PM21-particle driven NK cell
expansion.Presenter: Alicja J.
CopikAffiliation: University of Central
FloridaSession title: Virtual poster session
Kiadis Pharma Contacts
Kiadis
Pharma:Maryann Cimino, Sr. Manager, Corporate AffairsTel.
+1 617 710 7305m.cimino@kiadis.com |
Optimum Strategic
Communications:Mary Clark, Supriya Mathur, Hollie VileTel:
+44 203 950 9144David Brilleslijper (Amsterdam)Tel: +31 610 942
514kiadis@optimumcomms.com |
Dutch Translation/Nederlandse vertaling
Kiadis Pharma kondigt presentatie aan op
ISCT 2020 congres
Amsterdam, Nederland, 25 mei 2020 – Kiadis Pharma nv
(‘Kiadis’) (Euronext Amsterdam en Brussel: KDS), een
biofarmaceutische onderneming gericht op onderzoek in de klinische
fase, kondigt vandaag aan dat een presentatie over het Kiadis
NK-celtherapieprogramma is geaccepteerd voor ISCT congres
(International Society of Cell & Gene Therapy), welke
plaatsvindt op 28 en 29 mei 2020.
De ISCT-presentatie is nu beschikbaar op
http://www.isct2020.com/. Hier volgen nadere gegevens van de
presentatie:
·Presentatie nr. 228: De posterpresentatie
toont gegevens over een methode voor de hoge expansie van NK-cellen
(Natural Killer) met een uniek fenotype. Deze methode combineert
preactivering van NK-cellen met cytokinen (IL-12, IL-15, IL-18) en
expansie met het PM21-deeltjesproductieplatform van Kiadis.
Details van de presentatie
Titel: Cytokine-preactivering zorgt voor verdere
verbetering van op PM21 gebaseerde
NK-celexpansie.Presentator: Alicja J.
CopikLid van: University of Central
FloridaSessietitel: Virtuele posterpresentatie
Dit persbericht vormt een vertaling van het
gepubliceerde Engelstalige persbericht. Bij eventuele verschillen
is de tekst van het Engelstalige persbericht altijd
bepalend.
About Kiadis Pharma’s K-NK-Cell Therapies
Kiadis Pharma’s NK-cell programs consist of off-the-shelf and haplo
donor cell therapy products for the treatment of liquid and solid
tumors as adjunctive and stand-alone therapies.
The Company’s NK-cell PM21 particle technology enables improved
ex vivo expansion and activation of anti-cancer cytotoxic NK-cells
supporting multiple high-dose infusions. Kiadis Pharma’s
proprietary off-the-shelf NK-cell platform is based on NK-cells
from unique universal donors. The Kiadis Pharma off-the-shelf K-NK
platform can make NK-cell therapy product rapidly and economically
available for a broad patient population across a potentially wide
range of indications.
Kiadis Pharma is clinically developing K-NK003 for the treatment
of relapse/refractory acute myeloid leukemia. The Company is also
developing K-NK002, which is administered as an adjunctive
immunotherapeutic on top of HSCT and provides functional, mature
and potent NK-cells from a haploidentical family member. In
addition, the Company has pre-clinical programs evaluating NK-cell
therapy for the treatment of solid tumors.
About Kiadis PharmaFounded in 1997, Kiadis
Pharma is building a fully integrated biopharmaceutical company
committed to developing innovative therapies for patients with
life-threatening diseases. With headquarters in Amsterdam, the
Netherlands, and offices and activities across the United States,
Kiadis Pharma is reimagining medicine by leveraging the natural
strengths of humanity and our collective immune system to source
the best cells for life.
Kiadis Pharma is listed on the regulated market of Euronext
Amsterdam and Euronext Brussels since July 2, 2015, under the
symbol KDS. Learn more at www.kiadis.com.
Forward Looking Statements Certain statements,
beliefs and opinions in this press release are forward-looking,
which reflect Kiadis Pharma’s or, as appropriate, Kiadis Pharma’s
officers’ current expectations and projections about future events.
By their nature, forward-looking statements involve a number of
known and unknown risks, uncertainties and assumptions that could
cause actual results, performance, achievements or events to differ
materially from those expressed, anticipated or implied by the
forward-looking statements. These risks, uncertainties and
assumptions could adversely affect the outcome and financial
effects of the plans and events described herein. A multitude of
factors including, but not limited to, changes in demand,
regulation, competition and technology, can cause actual events,
performance, achievements or results to differ significantly from
any anticipated or implied development. Forward-looking statements
contained in this press release regarding past trends or activities
should not be taken as a representation that such trends or
activities will continue in the future. As a result, Kiadis Pharma
expressly disclaims any obligation or undertaking to release any
update or revisions to any forward-looking statements in this press
release as a result of any change in expectations or projections,
or any change in events, conditions, assumptions or circumstances
on which these forward-looking statements are based. Neither Kiadis
Pharma nor its advisers or representatives nor any of its
subsidiary undertakings or any such person’s officers or employees
guarantees that the assumptions underlying such forward-looking
statements are free from errors nor does either accept any
responsibility for the future accuracy of the forward-looking
statements contained in this press release or the actual occurrence
of the anticipated or implied developments. You should not place
undue reliance on forward-looking statements, which speak only as
of the date of this press release.